Cabaletta Bio

About Cabaletta Bio

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing and launching potentially breakthrough engineered T cell therapies for patients with autoimmune diseases. Their mission is to transform the treatment of autoimmune diseases by utilizing their innovative CABA® platform to deliver deep, durable, and potentially curative responses.

Products & Services

CABA-201:An investigational fully human CD19 chimeric antigen receptor (CAR) T cell therapy with a 4-1BB co-stimulatory domain, currently under development for systemic lupus erythematosus (SLE), myositis, systemic sclerosis, generalized myasthenia gravis, and other autoimmune diseases with high unmet need. It is designed as a one-time infusion to potentially eliminate B cells and enable an immune system reset.

CABA® Platform:A proprietary platform used to develop T cell therapies aimed at providing deep and durable responses for autoimmune diseases through B cell ablation.

rese-cel (CD19-CAR T cell therapy)

CABA-201

Specialties

Engineered T Cell Therapies Autoimmune Disease Treatment Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) CD19-CAR T Cell Therapy CAR T cell therapy Autoimmune diseases Lupus Myositis Systemic sclerosis Pemphigus vulgaris Myasthenia gravis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Offering T: - FT: Underwritten Offering	A: 150000000 MR: - FA: approximately $150 million FAN: 150000000	D: 2026-05-04 FD: 2026-05-04	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: approximately $100 million FAN: 100000000	D: 2025-06-11 FD: 2025-06-11	3 investors
3	RT: Public Offering T: - FT: Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2023-05-22 FD: 2023-05-22	4 investors
4	RT: Public Offering T: - FT: Public Offering	A: 87000000 MR: - FA: $87 million FAN: 87000000	D: 2023-05-17 FD: 2023-05-17	4 investors

Underwritten Offering Latest

2026-05-04

$150.0M

4 investors (Pro only)

Public Offering 2025-06-11

$100.0M

Public Offering 2023-05-22

$100.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Steven Nichtberger

President, Chief Executive Officer, and Co-Founder

S

Samik Basu

Chief Scientific Officer

G

Gwendolyn Binder

President, Science & Technology

D

David J. Chang

Chief Medical Officer

A

Arun Das

Chief Business Officer

S

Steve Gavel

Chief Commercial Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

Cabaletta Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised